Dennis J. Slamon

Feb 16, 2024 | uclahealth.org | Dennis J. Slamon

In the early 1990s, women who were diagnosed with the HER2-positive subtype of breast cancer weren’t expected to live more than three-to-five years after diagnosis. Now, depending on the stage of the cancer at diagnosis, women with HER2-positive breast cancer have among the highest survival rates of all women with breast cancer. That is thanksto the revolutionary breast cancer drug Herceptin, which was developed by a team ofscientists led by oncologist Dennis J.

Jan 22, 2024 | brnw.ch | Dennis J. Slamon |Hope Rugo |Nadia Harbeck

CLINICAL TRIAL UPDATES Background Since the initial development and approval of palbociclib, first-in-class cyclin-dependent kinase 4/6 (CDK4/6) inhibitor, for estrogen receptor–positive/human epidermal growth factor receptor 2–negative (ER+/HER2–) advanced breast cancer (ABC) on the basis of PALOMA-1 in 2015,1-4 the CDK4/6 inhibitor class has transformed the treatment landscape and, in combination with endocrine therapy (ET), has become the standard of care for the disease.5 PALOMA-2...

Jan 22, 2024 | ascopubs.org | Dennis J. Slamon |Hope Rugo |Nadia Harbeck

Clinical trials frequently include multiple end points that mature at different times. The initial report, typically based on the primary end point, may be published when key planned coprimary or secondary analyses are not yet available. Clinical trial updates provide an opportunity to disseminate additional results from studies, published in JCO or elsewhere, for which the primary end point has already been reported.

Jul 1, 2023 | targetedonc.com | Dennis J. Slamon

Dennis J. Slamon, MD, director of clinical/translational research, UCLA Jonsson Comprehensive Cancer Center and chairman and executive director of Translational Research in Oncology, discusses the rationale of the phase 3 NATALEE trial (NCT03701334) and describes ribociclib (Kisqali) for the treatment of patients with hormone receptor (HR)-positive/HER2-negative early breast cancer.

Jun 3, 2023 | targetedonc.com | Dennis J. Slamon

Dennis J. Slamon, MD, director of clinical/translational research, UCLA Jonsson Comprehensive Cancer Center and chairman and executive director of Translational Research In Oncology, discusses the key findings from the phase 3 NATALEE trial (NCT03701334) of ribociclib (Kisqali) with endocrine therapy as adjuvant treatment in patients with HR+/HER2- early breast cancer which were presented at ASCO 2023.